mild Procedure
Vertos Medical's first proprietary platform technology, mild (Minimally Invasive Lumbar Decompression), is the first minimally invasive surgical treatment for LSS. mild provides immediate and lasting relief from the condition, which affects 1.5 million patients a year in the U.S. alone.
Market cleared by the U.S. Food and Drug Administration for decompression of the lumbar spine, mild removes the bone or tissue causing the pressure on the nerves through a minimally invasive approach, or a small puncture of the skin, about the diameter of a pencil.
The minimally invasive nature of the mild procedure enables shorter in-patient therapy and recovery compared to other open surgical treatment options such as Laminotomy, Laminectomy and Spinal Fusion for LSS. Patients who undergo mild are typically discharged the day following the procedure.
The mild procedure can be performed with fluoroscopic guidance in an outpatient setting under local anesthesia or MAC support. Initial clinical data for mild indicate an average 75 percent reduction in pain and greater than 70 percent increase in mobility. In addition, most patients can decrease use of narcotics or pain medication at 6 weeks.1
mild is reimbursed by Medicare under existing treatment codes. Coverage varies by private insurers.
Vertos Medical's vision for the mild procedure includes future line extensions to treat foraminal stenosis, as well as treatment of various disc diseases. The company has a broad portfolio of pending U.S. and foreign patents for its proprietary mild platform technology.
FDA 510(k) Indications For Use
The Vertos mild Devices are specialized surgical instruments intended to be used to perform lumbar decompressive procedures for the treatment of various spinal conditions .
Become a fan of mild on 
Facebook
